Your browser doesn't support javascript.
loading
Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.
Huang-Doran, Isabel; Tomlinson, Patsy; Payne, Felicity; Gast, Alexandra; Sleigh, Alison; Bottomley, William; Harris, Julie; Daly, Allan; Rocha, Nuno; Rudge, Simon; Clark, Jonathan; Kwok, Albert; Romeo, Stefano; McCann, Emma; Müksch, Barbara; Dattani, Mehul; Zucchini, Stefano; Wakelam, Michael; Foukas, Lazaros C; Savage, David B; Murphy, Rinki; O'Rahilly, Stephen; Barroso, Inês; Semple, Robert K.
Afiliação
  • Huang-Doran I; The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom.
  • Tomlinson P; The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
  • Payne F; The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom.
  • Gast A; The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
  • Sleigh A; Metabolic Disease Group, Wellcome Trust Sanger Institute, Cambridge, United Kingdom.
  • Bottomley W; The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom.
  • Harris J; The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
  • Daly A; Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom.
  • Rocha N; National Institute for Health Research/Wellcome Trust Clinical Research Facility, Cambridge, United Kingdom.
  • Rudge S; Metabolic Disease Group, Wellcome Trust Sanger Institute, Cambridge, United Kingdom.
  • Clark J; The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom.
  • Kwok A; The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
  • Romeo S; Metabolic Disease Group, Wellcome Trust Sanger Institute, Cambridge, United Kingdom.
  • McCann E; The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom.
  • Müksch B; The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
  • Dattani M; Inositide Laboratory, Babraham Institute, Cambridge, United Kingdom.
  • Zucchini S; Inositide Laboratory, Babraham Institute, Cambridge, United Kingdom.
  • Wakelam M; The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge, United Kingdom.
  • Foukas LC; The National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, United Kingdom.
  • Savage DB; Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
  • Murphy R; Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy.
  • O'Rahilly S; Department of Clinical Genetics, Glan Clwyd Hospital, Rhyl, United Kingdom.
  • Barroso I; Department of Pediatrics, Children's Hospital, Cologne, Germany.
  • Semple RK; Section of Genetics and Epigenetics in Health and Disease, Genetics and Genomic Medicine Programme, UCL Institute of Child Health, London, United Kingdom.
JCI Insight ; 1(17): e88766, 2016 Oct 20.
Article em En | MEDLINE | ID: mdl-27766312
ABSTRACT
Obesity-related insulin resistance is associated with fatty liver, dyslipidemia, and low plasma adiponectin. Insulin resistance due to insulin receptor (INSR) dysfunction is associated with none of these, but when due to dysfunction of the downstream kinase AKT2 phenocopies obesity-related insulin resistance. We report 5 patients with SHORT syndrome and C-terminal mutations in PIK3R1, encoding the p85α/p55α/p50α subunits of PI3K, which act between INSR and AKT in insulin signaling. Four of 5 patients had extreme insulin resistance without dyslipidemia or hepatic steatosis. In 3 of these 4, plasma adiponectin was preserved, as in insulin receptor dysfunction. The fourth patient and her healthy mother had low plasma adiponectin associated with a potentially novel mutation, p.Asp231Ala, in adiponectin itself. Cells studied from one patient with the p.Tyr657X PIK3R1 mutation expressed abundant truncated PIK3R1 products and showed severely reduced insulin-stimulated association of mutant but not WT p85α with IRS1, but normal downstream signaling. In 3T3-L1 preadipocytes, mutant p85α overexpression attenuated insulin-induced AKT phosphorylation and adipocyte differentiation. Thus, PIK3R1 C-terminal mutations impair insulin signaling only in some cellular contexts and produce a subphenotype of insulin resistance resembling INSR dysfunction but unlike AKT2 dysfunction, implicating PI3K in the pathogenesis of key components of the metabolic syndrome.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Fosfatidilinositol 3-Quinases / Mutação Limite: Adolescent / Animals / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Fosfatidilinositol 3-Quinases / Mutação Limite: Adolescent / Animals / Child / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article